A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency

IRF4干扰素激活结构域的新功能突变会导致显性原发性免疫缺陷

阅读:7
作者:Romane Thouenon ,Loïc Chentout ,Nidia Moreno-Corona ,Lucie Poggi ,Emilia Puig Lombardi ,Benedicte Hoareau ,Yohann Schmitt ,Chantal Lagresle-Peyrou ,Jacinta Bustamante ,Isabelle André ,Marina Cavazzana ,Anne Durandy ,Jean-Laurent Casanova ,Lionel Galicier ,Jehane Fadlallah ,Alain Fischer ,Sven Kracker

Abstract

Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients' low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。